Home Page
Contact Us
CureShot Ventures: Transforming Autoimmune Disease Treatment
Specialist venture fund combining scientific excellence and AI innovation to create patient impact in autoimmune diseases - equal to heart disease and twice as prevalent as cancer.
At CureShot Ventures, we're revolutionizing autoimmune disease treatment by combining breakthrough therapeutic platforms with advanced AI.
Our team of world-class immunologists and data scientists is accelerating the path from research to patient care, targeting over 80 autoimmune conditions in a rapidly growing $200B+ market. Through strategic investments and innovative partnerships, we're aiming to bring hope to tens of millions of patients worldwide.
A Massive & Growing Healthcare Crisis
1
Disease Prevalence
Equal to heart disease and twice as prevalent as cancer, autoimmune diseases represent a massive healthcare burden.
2
Fastest Growing Category
Global autoimmune disease prevalence and associated spending is exploding, with the female population bearing the greatest disease burden.
3
Diverse Conditions
Includes rheumatoid arthritis, lupus, psoriasis, multiple sclerosis, and many other debilitating conditions.
About Us
Our Mission: Curing Autoimmune Diseases

At CureShot Ventures, we are pioneering a transformative approach to autoimmune disease treatment, combining cutting-edge science with strategic investment to create life-changing therapies. Our unwavering commitment drives us to develop innovative, disease-modifying solutions that address the root causes of autoimmune conditions, not just their symptoms. Through breakthrough research and collaborative partnerships, we're building a future where autoimmune diseases no longer limit human potential.
Strategic Investment Strategy
Pioneering Tomorrow's Cures
CureShot Ventures drives breakthrough innovations in autoimmune disease treatment through:
  • Harnessing cutting-edge AI and precision immunology to accelerate drug discovery.
  • Advancing next-generation tolerization platforms that target the root cause of autoimmune conditions.
  • Collaborating with world-renowned immunologists and clinical researchers to validate therapeutic approaches.
Value Creation
Transform Your Innovation Journey With Us
  • Deep Domain Expertise: Our team combines decades of biotech investment experience with pioneering research capabilities and successful commercialization track records.
  • Expansive Network: Access our established partnerships with leading academic institutions, pharmaceutical companies, and global investment firms.
  • Comprehensive Support: Benefit from hands-on guidance in clinical development, regulatory strategy, and commercial planning to accelerate your path to market.
  • Highly Levered Operating Team: Built from the ground up as an AI-centric venture firm, our team benefits from an ever-growing bench of AI agent talent.
Global Autoimmune Crisis
400M+
Lives Impacted
Affecting more people globally than cancer and heart disease combined.
$450B+
Economic Burden
Staggering annual healthcare costs draining both personal and national resources.
$200B
Market Opportunity
Explosive growth potential as precision medicine revolutionizes treatment approaches.
3
Family Members
Its personal, 3 family members of the Founders deeply impacted by severe autoimmune diseases.
With over 90% of autoimmune conditions lacking effective disease-modifying therapies, we stand at the threshold of a transformative opportunity to revolutionize patient care and create exceptional value with our companies.
Unequal Gender Impact
Autoimmune diseases disproportionately affect women, with research showing that women represent nearly 80% of all autoimmune patients worldwide.
This stark gender disparity represents one of the most significant yet under-addressed healthcare inequities of our time.
  • Autoimmune diseases rank among the top 5 leading causes of death for women under 65, surpassing both breast cancer and stroke in mortality rates
  • Emerging research shows an alarming 50% rise in autoimmune disease prevalence in developing nations over the past decade, creating an urgent need for accessible treatments
Gender Prevalence of Major & Other Target Autoimmune Diseases
Fastest Growing Global Disease Category
15% annual increase in diagnoses
Expertise Meets Execution
Scientific Excellence
Our pioneering breakthrough in Neuromyelitis Optica (NMO) achieved 90% reduction in disease activity, establishing a proven framework for targeting multiple autoimmune conditions.
Investment Expertise
Our world-class team combines over 100 years of experience across successful biotech exits, Phase III clinical trials, and dozens of venture investments, supported by a Scientific Advisory Board of leading immunology experts.
AI-Powered Precision
Our proprietary AI platform analyzes millions of data points to identify promising therapeutics, optimize trial protocols, and accelerate time-to-market by up to 40%, while reducing development costs.
AI-Powered Execution
Our proprietary multi-agentic AI platform enables enhanced company identification, diligence and portfolio company management, leveraging our operating team up to 10:1.
Guided by Visionaries: Our Founding Team
Dr. Reza Halse
Managing Partner
Merck Ventures
Dr. Michael Yeaman
Chief Scientific Advisor
UCLA / Lundquist Institute
Dr. Charlie Kim
Venture Partner
Verily / UCSF
Adam Roseman
Co-Founder & Special Advisor
SteadyIQ
Damon
AI Research Agent
Cindy
AI Diligence Agent
Yvonne
AI Operations Agent
Our founding team brings together an exceptional blend of expertise: seasoned venture capitalists with over 30 years combined experience in life sciences and technology investment, pioneering researchers who have developed breakthrough autoimmune therapies, and AI innovators with their team of brilliant and rapidly learning AI agents at the forefront of computational drug discovery. Led by industry veterans who have successfully guided many biotechnology and other companies from inception to exit, we combine deep scientific knowledge with proven business acumen. This unique convergence of talents positions us to transform autoimmune treatment paradigms through hands-on and AI-accelerated therapeutic development.
World-Leading Experts: Our Scientific Advisory Board
1
Neuroimmunology Pioneers
Distinguished researchers who have revolutionized our understanding of autoimmune neurological conditions, leading breakthrough clinical trials and establishing new diagnostic criteria for complex disorders.
2
Immunology Innovators
Renowned experts bridging fundamental immunology with clinical applications, developing novel therapeutic approaches and advancing our understanding of immune tolerance mechanisms.
3
Translational Research Leaders
Accomplished scientists who excel at converting laboratory discoveries into practical therapeutic solutions, with proven track records in bringing new treatments from bench to bedside.
4
Experienced Global Collaborators
International thought leaders who have built and led major research networks, fostering partnerships that accelerate the development of innovative autoimmune therapies.
Our Scientific Advisory Board
Dr. Gerald Nepom
As the founder of the Benaroya Research Institute and former director of the Immune Tolerance Network, Dr. Nepom is a pioneering force in immunogenetics and immune tolerance research. His groundbreaking work in T-cell tolerance mechanisms has revolutionized our understanding of autoimmune diseases, leading to innovative therapeutic approaches that have transformed patient care.
Dr. John Connolly
As Chief Scientific Officer at the Parker Institute for Cancer Immunotherapy, Dr. Connolly oversees a $400M research portfolio focused on breakthrough cancer treatments. His expertise in bridging autoimmune and cancer immunotherapy research provides crucial insights for advancing novel therapeutic approaches. His innovative work strengthens CureShot Ventures' mission to revolutionize autoimmune disease treatment.
Dr. Terry Smith
A distinguished professor at the University of Michigan, Dr. Smith revolutionized thyroid eye disease treatment as the primary developer of teprotumumab, the first FDA-approved therapy for this condition. His groundbreaking research in autoimmune thyroid disease and metabolic disorders continues to advance therapeutic innovation and improve patient outcomes worldwide.
Dr. Dean Wingerchuk
At Mayo Clinic, Dr. Wingerchuk serves as Chair of Neurology and Director of MS and Autoimmune Neurology. His pioneering work in developing diagnostic criteria for NMOSD has transformed the field of autoimmune neurology. His expertise in clinical trial design and therapeutic outcome measurement continues to shape treatment standards globally.
Dr. Michael Levy
Leading research at Massachusetts General Hospital, Dr. Levy specializes in autoimmune diseases of the central nervous system. His innovative work in biomarker development and therapeutic approaches for NMOSD has significantly advanced clinical care standards and treatment options for patients with complex neuroimmune disorders.
Dr. Sean Pittock
As founder of Mayo Clinic's first Autoimmune Neurology Clinic and director of the Neuroimmunology Research Lab, Dr. Pittock has transformed the field of autoimmune neurology. His pioneering research in biomarker discovery has led to two FDA-approved therapies, significantly improving treatment options for patients.
Dr. Tanuja Chitnis
As Director of the CLIMB Program at Brigham and Women's Hospital, Dr. Chitnis leads groundbreaking research in precision medicine and translational neuroimmunology. With over 350 peer-reviewed publications, her work in biomarker research and therapeutic development has significantly advanced treatment options for multiple sclerosis and related autoimmune conditions.
Dr. Ben Greenberg
A distinguished neuroimmunologist at UT Southwestern, Dr. Greenberg has made remarkable contributions to both adult and pediatric autoimmune disorder treatment. Through his leadership of the CONQUER biorepository and involvement in over 20 clinical trials, he continues to drive innovation in biomarker identification and therapeutic development.
Dr. Jeff Bennett
As Professor of Neurology and Ophthalmology at the University of Colorado, Dr. Bennett has made significant contributions to understanding neuro-ophthalmic disorders. His expertise in B cell mechanisms and development of Aquaporumab demonstrates his innovative approach to advancing NMOSD treatment. His treatment protocol for acute optic-neuritis has become a standard in the field.
Dr. Friedemann Paul
As Head of the Clinical Research Center at the Charité Berlin, Dr. Paul brings exceptional expertise in neurological research and rare diseases. His role as Associate Editor of "Neurology: Neuroimmunology and Neuroinflammation" and service as Medical Consultant for EU Research Programmes on Rare Diseases reflects his global influence in advancing neuroimmunological research.
AI-Powered Investment Excellence
Data-Driven Insights
Our proprietary AI algorithms analyze millions of scientific papers, clinical trials, and market data points to identify breakthrough opportunities in autoimmune therapeutics. This comprehensive analysis helps us spot emerging therapies years before they reach mainstream attention.
Predictive Analytics
Advanced machine learning models evaluate therapeutic potential, clinical trial success probability, and market dynamics with unprecedented accuracy. By processing historical data from over 25,000 clinical trials, we can forecast development timelines and optimize investment timing.
Personalized Recommendations
Our AI platform delivers strategic insights customized to each therapeutic candidate's unique profile, considering factors like mechanism of action, patient population, and market positioning. This precision approach enables us to make confident, evidence-based investment decisions that maximize potential returns.
AI-Powered Investment Excellence in Therapeutics

1

2

3

4

1
Smart Opportunity Discovery
Investment Team, Scientific Advisory Board & AI analyze global biotech landscape to uncover high-potential therapeutic innovations
2
Clinical Development Enhancement
Accelerate trials and boost success rates through extensive operational experience and predictive analytics
3
Strategic Portfolio Optimization
Data-driven operational support to maximize capital efficiency
4
Value Maximization
Advanced modeling for optimal value creation
Our world-class Scientific Advisory Board and sophisticated use of AI transform traditional investment approaches into precision-driven decisions.
By leveraging advanced analytics at each stage, we identify and accelerate the development of breakthrough autoimmune therapies. This unique combination of technological innovation and therapeutic expertise creates sustainable competitive advantages in the rapidly evolving biotech landscape.
The NMO Blueprint: Team Collaboration
1
Work with Research Foundation
Created world's largest NMO biobank with 10,000+ samples and united 50+ global research institutions
2
Breakthrough Discovery
Identified 3 novel predictive biomarkers that revolutionized early NMO diagnosis
3
Therapeutic Innovation
Accelerated development of 6 promising drug candidates through clinical trials
4
Market Impact
Achieved unprecedented success with 4 FDA-approved therapies over only ten years, transforming patient care
Science Meets Impact
Transforming Patient Outcomes
Creating Sustainable Healthcare Solutions:
  • 25% of carried interest directly funds patient advocacy and support programs.
  • Developing innovative solutions that combine breakthrough science with real-world affordability and accessibility.
Proven Track Record
Our Team's Exceptional Performance:
  • Successfully led 4 therapeutics companies through IPOs, maximizing value and market impact
  • Orchestrated 6 high-value therapeutics company M&A exits, creating substantial returns for stakeholders
Join Us in Transforming Autoimmune Healthcare
Autoimmune diseases affect over 50 million Americans, yet treatments remain limited and often ineffective. At CureShot Ventures, we combine deep scientific expertise, cutting-edge technology, and forward-thinking investment strategies to accelerate breakthrough therapies. Our unique approach bridges the gap between innovative research and life-changing treatments, creating meaningful impact for patients while generating exceptional returns for investors.
Are you focused on technology that improves the lives of those suffering from autoimmune disease? Partner with us to fast-track your innovative therapies from breakthrough discovery to market success, backed by our proven expertise and strategic support.
© 2025 CURESHOT VENTURES, All Rights Reserved. Legal Notice